Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer
Trial Details
- NCT ID
- NCT05657743
- Phase
- NA
- Sponsor
- Alpha Tau Medical LTD.
- Status
- RECRUITING
- Cancer Type
- Pancreatic Cancer
- Interventions
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Locations (sample)
- Holon, Israel|32.01034,34.77918
- Jerusalem, Israel|31.76904,35.21633
Key Eligibility Criteria
- Histologically and/or cytologically proven locally advanced or metastatic pancreatic adenocarcinoma
- Patients must have i) received at least one line of chemotherapy OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still n…
- Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician
- Interstitial radiation indication validated by a multidisciplinary team
For full eligibility, visit ClinicalTrials.gov.